An FDA spokesperson told CNBC the agency will review the information, as it is set to vote on the vaccine’s emergency use authorization.
Unlike Pfizer and Moderna, Novavax isn’t mRNA-based — a component that was shown to be more effective at protecting against COVID-19. With a 90 percent efficacy rate, the potential fourth option for a vaccine was also clinically tested before the omicron variant swept across the U.S.
Before Novavax is rolled out, the FDA and CDC will have to authorize it.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
